Residency · Residency · Neurology

Classification of Seizures and Epilepsy Syndromes

Overview

Accurate seizure and epilepsy classification forms the foundation for treatment selection and prognostication. The 2017 ILAE classification provides a multi-level framework progressing from seizure type to epilepsy type to epilepsy syndrome. Distinguishing focal from generalized seizures has direct pharmacotherapeutic implications, as certain medications that are effective for one type can worsen the other. Epilepsy syndrome identification further refines prognosis, guides genetic counseling, and informs decisions about treatment duration.

2017 ILAE Classification Framework

Level 1: Seizure Type

Focal onset seizures arise in networks limited to one hemisphere. They are further classified by level of awareness (aware, formerly called simple partial, versus impaired awareness, formerly complex partial) and by the dominant initial feature (motor onset or non-motor onset). Motor onset types include automatisms, clonic, tonic, atonic, hyperkinetic, myoclonic, and epileptic spasms. Non-motor onset types include sensory, cognitive, emotional, and autonomic features. A focal seizure may also evolve to become a bilateral tonic-clonic seizure, which was formerly termed secondary generalization.

Generalized onset seizures arise in and rapidly engage bilateral networks. Motor types include tonic-clonic, clonic, tonic, myoclonic, myoclonic-tonic-clonic, myoclonic-atonic, atonic, and epileptic spasms. Non-motor generalized seizures are the absence seizures: typical, atypical, myoclonic absence, and eyelid myoclonia with absence.

Unknown onset seizures are those for which insufficient information is available to classify the origin.

Level 2: Epilepsy Type

At the epilepsy type level, focal epilepsy features predominantly focal seizures. Generalized epilepsy features predominantly generalized seizures with generalized spike-wave discharges on EEG. Combined generalized and focal epilepsy is seen in syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. An unknown category exists for cases that cannot be classified.

Level 3: Epilepsy Syndrome

An epilepsy syndrome is defined by a cluster of features including seizure type or types, EEG findings, age of onset, comorbidities, and natural history. Identifying the specific syndrome has major implications for treatment choices, prognosis, and genetic counseling.

Key Epilepsy Syndromes

Juvenile Myoclonic Epilepsy (JME)

JME typically presents between ages 12 and 18 with a characteristic triad of myoclonic jerks (especially in the morning), generalized tonic-clonic seizures, and absence seizures (in about 30% of patients). The EEG shows 4-6 Hz generalized polyspike-and-wave discharges. Seizures are commonly provoked by sleep deprivation, alcohol, and photic stimulation. JME responds well to valproate, levetiracetam, or lamotrigine, though lamotrigine must be used with caution as it may worsen myoclonus. This is a lifelong condition with a relapse rate of approximately 90% if medication is withdrawn. Carbamazepine and phenytoin must be avoided because they can exacerbate both myoclonus and absence seizures.

Childhood Absence Epilepsy (CAE)

CAE presents between ages 4 and 10, with a peak at 5-7 years. The seizures are brief staring spells lasting 5-30 seconds with abrupt onset and offset, occurring up to hundreds of times per day. The EEG signature is 3 Hz generalized spike-and-wave, which is reliably activated by hyperventilation. First-line treatment is ethosuximide for absence-only epilepsy or valproate when generalized tonic-clonic seizures are also present. The SANAD trial and dedicated childhood absence epilepsy studies confirmed ethosuximide as the preferred agent for pure absence. The prognosis is good, with approximately 70% of patients remitting by adolescence, though some evolve into JME.

Temporal Lobe Epilepsy (TLE)

TLE is the most common focal epilepsy in adults. The mesial temporal subtype is associated with hippocampal sclerosis and often a history of prolonged febrile seizures in childhood. The typical seizure semiology includes an epigastric rising sensation as an aura, impaired awareness, oroalimentary automatisms (lip smacking, chewing), and unilateral hand automatisms with contralateral dystonic posturing. The EEG shows temporal sharp waves interictally and rhythmic temporal theta at seizure onset. MRI reveals hippocampal atrophy and T2/FLAIR hyperintensity on the affected side. TLE is frequently drug-resistant, but patients with mesial TLE are excellent surgical candidates; anterior temporal lobectomy achieves seizure freedom in approximately 70%.

Frontal Lobe Epilepsy

Frontal lobe epilepsy is the second most common focal epilepsy. Seizures tend to be brief, frequent, and often nocturnal, with prominent motor features. Hyperkinetic seizures involve bilateral leg movements, cycling, or complex thrashing. These events may be misdiagnosed as parasomnias or psychogenic events. The EEG may be normal or show only subtle frontal discharges, often necessitating video-EEG for definitive diagnosis. Supplementary motor area seizures produce asymmetric tonic posturing in the characteristic "fencing posture."

Self-Limited Epilepsy with Centrotemporal Spikes (SeLECTS)

Formerly known as benign epilepsy with centrotemporal spikes (BECTS), SeLECTS presents between ages 3 and 13 with focal seizures featuring facial twitching, drooling, and speech arrest, often occurring during sleep. The EEG shows centrotemporal (rolandic) spikes that are activated by sleep. The course is benign, with resolution by mid-adolescence. Many patients do not require treatment; when treatment is necessary, levetiracetam or oxcarbazepine are preferred options.

Lennox-Gastaut Syndrome (LGS)

LGS is a severe childhood-onset epilepsy beginning between ages 1 and 7. It features multiple seizure types, with tonic seizures being the most characteristic along with atonic seizures (drop attacks), atypical absence, and myoclonic seizures. The EEG shows slow (less than 2.5 Hz) spike-and-wave and generalized paroxysmal fast activity in sleep. Intellectual disability is common. The epilepsy is typically drug-resistant; treatment involves valproate, clobazam, rufinamide, lamotrigine, and cannabidiol (Epidiolex). Corpus callosotomy may be considered for disabling drop attacks.

Dravet Syndrome

Dravet syndrome results from SCN1A mutations affecting the sodium channel Nav1.1, with onset in the first year of life. It begins with prolonged febrile and afebrile seizures that are often hemiconvulsive, then evolves to include multiple seizure types. The epilepsy is refractory to most antiseizure medications, and sodium channel blockers (carbamazepine, phenytoin, lamotrigine) must be avoided as they worsen seizures. Treatment relies on valproate, clobazam, stiripentol, cannabidiol, and fenfluramine. Cognitive and developmental regression are expected, and the risk of SUDEP is high.

West Syndrome (Infantile Spasms)

West syndrome presents between 3 and 12 months of age with the triad of epileptic spasms (clusters of brief flexor or extensor spasms), developmental regression, and hypsarrhythmia on EEG. Treatment with ACTH or vigabatrin (especially when tuberous sclerosis complex is the underlying cause) must be initiated urgently to limit developmental impact.

Importance of Accurate Classification for Treatment

Medications That Worsen Certain Seizure Types

Carbamazepine, oxcarbazepine, and phenytoin may worsen absence seizures, myoclonic seizures, and atonic seizures. These sodium channel blockers should be avoided in generalized epilepsy syndromes including JME, CAE, LGS, and Dravet syndrome. Lamotrigine may worsen myoclonus in JME, though it can be effective for generalized tonic-clonic and absence seizures at lower doses with careful titration. Vigabatrin may worsen myoclonic and absence seizures.

Broad-Spectrum vs Narrow-Spectrum ASMs

Broad-spectrum agents are effective for both focal and generalized seizures and include valproate, levetiracetam, lamotrigine, topiramate, zonisamide, clobazam, and brivaracetam. Narrow-spectrum agents are primarily effective for focal seizures and may worsen generalized epilepsy; these include carbamazepine, oxcarbazepine, phenytoin, lacosamide, gabapentin, and pregabalin.

<image>A hierarchical diagram illustrating the 2017 ILAE classification framework. The top level shows "Seizure Type" branching into focal onset (with sub-branches for aware vs impaired awareness, motor vs non-motor, and focal to bilateral tonic-clonic), generalized onset (motor: tonic-clonic, clonic, tonic, myoclonic, atonic; non-motor: typical absence, atypical absence), and unknown onset. The middle level shows "Epilepsy Type" (focal, generalized, combined, unknown). The bottom level shows "Epilepsy Syndrome" with examples mapped to each type (TLE and frontal lobe for focal; JME and CAE for generalized; Dravet and LGS for combined). Etiology (structural, genetic, infectious, metabolic, immune, unknown) is shown as a cross-cutting dimension.</image>

<image>An EEG pattern comparison panel showing representative EEG recordings for key epilepsy syndromes. Panel 1: 3 Hz generalized spike-and-wave in childhood absence epilepsy (with hyperventilation activation noted). Panel 2: 4-6 Hz generalized polyspike-and-wave in juvenile myoclonic epilepsy. Panel 3: temporal sharp waves and rhythmic temporal theta onset in temporal lobe epilepsy. Panel 4: centrotemporal spikes activated by sleep in SeLECTS. Panel 5: slow (<2.5 Hz) spike-and-wave and generalized paroxysmal fast activity in Lennox-Gastaut syndrome. Panel 6: hypsarrhythmia in West syndrome. Each panel is annotated with the syndrome name, typical age, and key clinical features.</image>

<image>A clinical decision aid showing which antiseizure medications are appropriate or contraindicated by epilepsy syndrome. A matrix format lists common ASMs on one axis and epilepsy syndromes (JME, CAE, TLE, LGS, Dravet, SeLECTS) on the other. Green cells indicate first-line/effective, yellow indicates potentially effective with caution, and red indicates contraindicated or may worsen seizures. Key contraindications highlighted: sodium channel blockers in JME, CAE, Dravet; vigabatrin in absence/myoclonic epilepsy.</image>

Clinical Pearls

Always classify both the seizure type and the epilepsy syndrome before choosing an antiseizure medication. Using a narrow-spectrum sodium channel blocker in a patient with JME can worsen myoclonus and absence seizures. Hyperventilation for 3-5 minutes during an EEG is the most reliable activating procedure for childhood absence epilepsy, and failure to perform it represents a missed diagnostic opportunity. Morning myoclonic jerks, especially with dropped objects at breakfast, in an adolescent strongly suggest JME. Temporal lobe epilepsy with hippocampal sclerosis is the most common surgically remediable epilepsy syndrome. SCN1A testing should be performed early in any infant with prolonged febrile seizures or refractory epilepsy, because identifying Dravet syndrome prevents the harmful use of sodium channel blockers. The 3 Hz spike-and-wave EEG pattern is so characteristic of childhood absence epilepsy that it is virtually diagnostic in the appropriate clinical context. JME is a lifelong condition, and medication withdrawal should be approached with extreme caution given the 90% relapse rate.

References

• Fisher RS, et al. Operational classification of seizure types by the ILAE. Epilepsia. 2017;58(4):522-530.
• Scheffer IE, et al. ILAE classification of the epilepsies. Epilepsia. 2017;58(4):512-521.
• Glauser TA, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790-799.
• Panayiotopoulos CP. A Clinical Guide to Epileptic Syndromes and Their Treatment. 2nd ed. Springer; 2010.
• Wirrell EC, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes. Epilepsia. 2022;63(6):1333-1348.

Read this lecture as Markdown